AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6342219
Drug: Low maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low maintenance dose of prednisone (30 mg/day) and antilymphocyte globulin (ALG)
Trial: 6342219
Drug: High maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High maintenance doses of prednisone (2 mg/kg/day with tapering) and intravenous methylprednisolone (IVMP)
Trial: 29228935
Drug: Nebulized 2.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized 2.0% morphine
Trial: 9568649
Drug: Single antibiotic
RxNorm normalized name: BACITRACIN ZINC 500 [iU] in 1 g TOPICAL OINTMENT [Single Antibiotic]
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single antibiotic agent treatment in group A
Trial: 9568649
Drug: Triple-agent antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-agent antibiotics in group B
Trial: 8041524
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of spatula and swab
Trial: 21595877
Drug: Systematic program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic program for increasing influenza vaccine uptake among HCWs
Trial: 12701008
Drug: Endoscopic epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoscopic epinephrine injection therapy
Trial: 9363412
Drug: Clonidine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (maximum daily dose: 0.6 mg)
Trial: 30736383
Drug: Mangiferin +
RxNorm normalized name: mangiferin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mangiferin + Luteolin (PHE: 50 mg/day; MLE: 140 mg/day)
Trial: 30736383
Drug: Mangiferin +
RxNorm normalized name: mangiferin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mangiferin + Luteolin (PHE: 100 mg/day; MLE: 420 mg/day)
Trial: 16732060
Drug: Intracoronary radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary radiation therapy (ICRT) with 17 Gy
Trial: 1351673
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with Triazolam (0.250 mg)
Trial: 1351673
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with Zopiclone (7.5 mg)
Trial: 3241278
Drug: Hydrochlorothiazide (diuretic)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (diuretic)
Trial: 23332861
Drug: FF/VI 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/VI 100/25 μg
Trial: 30469433
Drug: hypothermic histidine‐tryptophan‐ketoglutarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hypothermic histidine‐tryptophan‐ketoglutarate (HTK) solution
Trial: 24849441
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment (medication group, 94 lesions)
Trial: 22595272
Drug: Rapid diagnostic
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid diagnostic tests (RDTs), artemether-lumefantrine (AL), amoxicillin
Trial: 19019358
Drug: Metformin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1 g two times per day, n = 36)
Trial: 19019358
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pill (OCP) (35 microg ethinyl E(2)‐2 mg cyproterone acetate, n = 30)
Trial: 12187499
Drug: Antiretrovirals alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretrovirals alone or in combination with HU and IL-2
Trial: 8695837
Drug: Quinine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (30 mg/kg/d, days 1 to 5; continuous intravenous infusion beginning 24 hours before mitoxantrone infusion)
Trial: 8695837
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (mitoxantrone 12 mg/m2/d, days 2 to 5 and cytarabine 1 g/m2/12 h, days 1 to 5)
Trial: 1752115
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta (intravenous)
Trial: 30679284
Drug: Route of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of medication
Trial: 12579025
Drug: One-step povidone-iodine
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-step povidone-iodine topical gel
Trial: 16966616
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol maleate twice daily
Trial: 1874212
Drug: Propofol 20‐200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 20‐200 mg h‐1
Trial: 24104763
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propofol and alfentanil
Trial: 6115732
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg propranolol
Trial: 20096821
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) plus metformin
Trial: 31677181
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus metformin (Plac/Met)
Trial: 31358588
Drug: Artemisinin-based combination
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin-based combination therapy (ACT); specific details on dosage and duration not provided.
Trial: 26209863
Drug: ENG implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENG implant inserted within 48 h after delivery
Trial: 1945579
Drug: PRP-T mixed
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-T mixed with DTP vaccine in a single syringe (Group A)
Trial: 7021072
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg soluble aspirin
Trial: 30062716
Drug: Paricalcitol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol (2 μg/day for 24 weeks)
Trial: 22978098
Drug: Yupei Qisun
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yupei Qisun Sequential Method (YQSM) combined with IVF/ICSI
Trial: 20139233
Drug: Testosterone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (5 mg/d) in elderly men
Trial: 20139233
Drug: DHEA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (50 mg/d) in elderly women
Trial: 21278555
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release epidural morphine (DepoDur)
Trial: 19038468
Drug: Concomitant and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant and adjuvant short-term hormonal treatments with curative radiotherapy
Trial: 1674105
Drug: Ursodiol (13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodiol (13 to 15 mg per kilogram of body weight per day)
Trial: 26242122
Drug: Integrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative medicine treatment group (anti‐virus Western medicine plus CQG)
Trial: 26242122
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine treatment group (treated with anti‐virus Western medicine)
Trial: 16878257
Drug: Genotyping-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotyping-based treatment switch (group 1)
Trial: 1324645
Drug: Amoxicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (500 mg three times daily for 5 days)
Trial: 6370581
Drug: 4% aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% aqueous sodium lauryl sulfate (SLS) solution applied for 24 hours
Trial: 21144223
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray (FFNS), 110 micrograms, once daily for 4 weeks
Trial: 19428097
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray (FFNS)
Trial: 7978086
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Treatment (CB) for ASPs
Trial: 7978086
Drug: Relationship Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relationship Enhancement Treatment for ASPs
Trial: 7767
Drug: Formula 2
RxNorm normalized name: Formula 21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula 2 (3.0 gm of protein per 100 ml, 60:40)
Trial: 7767
Drug: Formula 1
RxNorm normalized name: Abena Man Formula 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula 1 (1.5 gm of protein per 100 ml, 60:40)
Trial: 7767
Drug: Formula 3
RxNorm normalized name: Formula 3200
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formula 3 (1.5 gm of protein per 100 ml, 18:82)
Trial: 19417866
Drug: 30% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% carbamide peroxide with 5% potassium nitrate (treatment A)
Trial: 19417866
Drug: 30% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% carbamide peroxide without potassium nitrate (treatment B)
Trial: 11579707
Drug: Methotrexate (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (starting at 7.5 mg/week, max 20 mg/week)
Trial: 26166166
Drug: Octreotide long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide long-acting release (OctLAR) 40 mg monthly
Trial: 23214253
Drug: Control (antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (antibiotics plus hemostatics with usual wound care)
Trial: 12271412
Drug: Potassium iodide
RxNorm normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium iodide (KI) 100 mg per day starting 2 days before (131)I-lipiodol administration and continuing until 2 weeks after therapy; n=31
Trial: 31840388
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral antiviral use pre- and post-treatment
Trial: 22609501
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 25 microgram/kg/min
Trial: 22609501
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 50 microgram/kg/min
Trial: 22609501
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 75 microgram/kg/min
Trial: 16710252
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with enalapril (10 mg)
Trial: 16968506
Drug: Nurse-administered propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered propofol sedation with BIS visible (Phase 1)
Trial: 16968506
Drug: Nurse-administered propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered propofol sedation with BIS visible (Phase 2)
Trial: 25098596
Drug: Intrapulmonary percussive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapulmonary percussive ventilation (IPV) combined with chest physical therapy (CPT)
Trial: 25098596
Drug: Traditional standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional standard chest physical therapy (CPT)
Trial: 22321885
Drug: Palonosetron (drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron (drug A)
Trial: 22333250
Drug: Calcineurin inhibitors
RxNorm normalized name: Calcineurin inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcineurin inhibitors (CNI)
Trial: 8233296
Drug: Hyperfractionated accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionated accelerated radiotherapy (2 x 1.6 Gy/day, 5 days per week: total dose, 64‐67.2 Gy) and simultaneous intravenous carboplatin (60 mg/m2, days 1‐5 and 29‐33).
Trial: 25123600
Drug: Zonisamide 200
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide 200 mg
Trial: 25123600
Drug: Zonisamide 400
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide 400 mg
Trial: 20116047
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation (DBS) of the ventral capsule/ventral striatum
Trial: 15864805
Drug: Intravascular radiation
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular radiation therapy (IRT) with iridium (Ir)-192 (n = 60)
Trial: 6510013
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 mg), amiloride (2.5 mg), and timolol (10 mg) taken before food
Trial: 27191689
Drug: Bortezomib-PLD (bortezomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib-PLD (bortezomib plus pegylated liposomal doxorubicin 30 mg/m² intravenously on day 4)
Trial: 27191689
Drug: Bortezomib alone
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib alone (1.3 mg/m² intravenously on days 1, 4, 8, and 11 of every 21-day cycle)
Trial: 1971516
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg once daily
Trial: 26420821
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy (10 sessions)
Trial: 15872029
Drug: bezafibrate retard
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate retard 400 mg once daily
Trial: 15872029
Drug: triglycerides (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triglycerides (50 mg/dL increment)
Trial: 12079015
Drug: Intra-articular bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular bupivacaine 150 mg + morphine 4 mg
Trial: 353682
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate intravenously, 30 mg/sq m every six hours (conventional dose)
Trial: 7168176
Drug: 50 mcg
RxNorm normalized name: D3, 50 mcg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mcg sulprostone administered intramurally into the cervix
Trial: 7168176
Drug: 4 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 injections of 250 micrograms sulprostone administered intragluteally at 4 hour intervals
Trial: 20332140
Drug: Triplet chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplet chemotherapy
Trial: 8876342
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (4 . day‐1 x 5 g Cr.H2O + 2 g sucrose)
Trial: 8876342
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 . day‐1 x 5 g Polycose + 2 g sucrose)
Trial: 6654627
Drug: Atropine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (3 X 0.66 mg)
Trial: 6654627
Drug: Atropine +
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine + Cyproheptadine (3 X 4 mg)
Trial: 6654627
Drug: Carbenoxolone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone (3 X 100-3 X 50 mg)
Trial: 26944891
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of 2 units of botulinum toxin type A (BTX‐A)
Trial: 26944891
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of 4 units of botulinum toxin type A (BTX‐A)
Trial: 25252807
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy intervention (CBTi) for fear of falling
Trial: 22698066
Drug: Sugammadex 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 4 mg.kg(‐1) administered at 1‐2 post‐tetanic count (deep blockade)
Trial: 22698066
Drug: Neostigmine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 50 μg.kg(‐1) plus atropine 10 μg.kg(‐1) administered at the re‐appearance of the second twitch of a train‐of‐four stimulation (moderate blockade)
Trial: 25048848
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% 250 mg imiquimod ointment followed by intradermal TIV
Trial: 25048848
Drug: Topical aqueous-cream
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aqueous-cream followed by intramuscular TIV
Trial: 18471387
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of contrast agent
Trial: 18471387
Drug: 80 mL
RxNorm normalized name: urinary bag 480 mL MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mL of contrast agent
Trial: 18471387
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL of contrast agent
Trial: 18471387
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL of physiological serum at a rate of 4 ml/s
Trial: 12915640
Drug: 3 IU
RxNorm normalized name: Vitamin A/Vitamin D 1250 IU-133 IU Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 IU GH/m(2).d (approximately 0.033 mg/kg.d)
Trial: 12915640
Drug: 6 IU
RxNorm normalized name: Coenzyme Q10/Vitamin E 30 MG-6 IU Oral Capsule, Liquid Filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 IU GH/m(2).d (approximately 0.067 mg/kg.d)
Trial: 10555031
Drug: Serum COMP
RxNorm normalized name: TITANIUM DIOXIDE 4.9 g in 100 g / OCTINOXATE 2 g in 100 g TOPICAL POWDER [ISAKNOX AGELESS SERUM COMPACT 23]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum COMP levels in OA group (1,208.57 ± 487.47 ng/ml)
Trial: 10555031
Drug: Serum COMP
RxNorm normalized name: TITANIUM DIOXIDE 4.9 g in 100 g / OCTINOXATE 2 g in 100 g TOPICAL POWDER [ISAKNOX AGELESS SERUM COMPACT 23]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum COMP levels in age > or = 65 group (1,302.1 ± 496.7 ng/ml)
Trial: 1750602
Drug: Single-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oral famotidine
Trial: 1750602
Drug: Double-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose oral ranitidine
Trial: 27913991
Drug: Preservative-free dorzolamide/timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free dorzolamide/timolol fixed combination (triple PF regimen)
Trial: 7712677
Drug: Lidocaine infusion
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine infusion (8-hour initial infusion followed by 40-hour infusion)
Trial: 7712677
Drug: Placebo (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (after 8-hour lidocaine infusion)
Trial: 2565329
Drug: NAD (nadolol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAD (nadolol, 80 mg/day)
Trial: 2565329
Drug: AT (atenolol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT (atenolol, 100 mg/day)
Trial: 31757033
Drug: High-dose GSPE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GSPE (400 mg/day)
Trial: 31757033
Drug: Low-dose GSPE
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose GSPE (200 mg/day)
Trial: 21875472
Drug: Intravesical gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical gemcitabine 2000 mg
Trial: 21875472
Drug: Original intravesical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original intravesical chemotherapy
Trial: 16961291
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 300 mg three times daily
Trial: 12965314
Drug: Preop‐TEA (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preop‐TEA (8 mL of 0.25% bupivacaine plus fentanyl 50 microg in 2 mL administered preoperatively)
Trial: 12965314
Drug: Postop‐TEA (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postop‐TEA (no medication administered preoperatively and intraoperatively, postoperative analgesia maintained with patient‐controlled epidural analgesia with bupivacaine and fentanyl solution)
Trial: 10852444
Drug: Hypoglycemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemic clamp of 2.9 +/‐ 0.1 mmol/L after euglycemia (5.1 +/‐ 0.1 mmol/L) on day 1